Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17143520rdf:typepubmed:Citationlld:pubmed
pubmed-article:17143520lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:17143520lifeskim:mentionsumls-concept:C0664336lld:lifeskim
pubmed-article:17143520lifeskim:mentionsumls-concept:C0006118lld:lifeskim
pubmed-article:17143520lifeskim:mentionsumls-concept:C0893445lld:lifeskim
pubmed-article:17143520lifeskim:mentionsumls-concept:C0004358lld:lifeskim
pubmed-article:17143520pubmed:issue1lld:pubmed
pubmed-article:17143520pubmed:dateCreated2006-12-4lld:pubmed
pubmed-article:17143520pubmed:abstractTextSurvivin is a member of the inhibitor of apoptosis protein (IAP) family and is frequently expressed in cancers, including meningiomas and gliomas. Survivin may be associated with tumor progression and poor prognosis of patients with brain tumors. Using ELISA and immunoblot analysis we asked whether survivin is capable of eliciting a humoral immune response in patients with meningiomas and gliomas. Survivin-specific antibodies were detected in 5 of 42 (11.9%) patients with meningiomas and 3 of 35 (8.6%) patients with malignant gliomas of the WHO grades 3 and 4, but not in healthy controls. Tumors of patients with detectable anti-survivin antibodies demonstrated survivin expression in at least 20% of the tumor cells as assessed by immunohistochemistry. We conclude that patients with meningiomas and malignant gliomas can mount a high-titer IgG immune response against the 'universal' tumor-associated antigen survivin. Anti-survivin antibodies may represent attractive tools for diagnosis and follow-up of brain tumors.lld:pubmed
pubmed-article:17143520pubmed:languageenglld:pubmed
pubmed-article:17143520pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17143520pubmed:citationSubsetIMlld:pubmed
pubmed-article:17143520pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17143520pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17143520pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17143520pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17143520pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17143520pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17143520pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17143520pubmed:statusMEDLINElld:pubmed
pubmed-article:17143520pubmed:monthJanlld:pubmed
pubmed-article:17143520pubmed:issn1019-6439lld:pubmed
pubmed-article:17143520pubmed:authorpubmed-author:RainovNikolai...lld:pubmed
pubmed-article:17143520pubmed:authorpubmed-author:SölingArianeAlld:pubmed
pubmed-article:17143520pubmed:authorpubmed-author:WeigleBerndBlld:pubmed
pubmed-article:17143520pubmed:authorpubmed-author:SchmitzMarcMlld:pubmed
pubmed-article:17143520pubmed:authorpubmed-author:JacobRolandRlld:pubmed
pubmed-article:17143520pubmed:authorpubmed-author:HolzhausenHan...lld:pubmed
pubmed-article:17143520pubmed:authorpubmed-author:PluggeEva-Mar...lld:pubmed
pubmed-article:17143520pubmed:authorpubmed-author:IllertJörgJlld:pubmed
pubmed-article:17143520pubmed:issnTypePrintlld:pubmed
pubmed-article:17143520pubmed:volume30lld:pubmed
pubmed-article:17143520pubmed:ownerNLMlld:pubmed
pubmed-article:17143520pubmed:authorsCompleteYlld:pubmed
pubmed-article:17143520pubmed:pagination123-8lld:pubmed
pubmed-article:17143520pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:17143520pubmed:meshHeadingpubmed-meshheading:17143520...lld:pubmed
pubmed-article:17143520pubmed:meshHeadingpubmed-meshheading:17143520...lld:pubmed
pubmed-article:17143520pubmed:meshHeadingpubmed-meshheading:17143520...lld:pubmed
pubmed-article:17143520pubmed:meshHeadingpubmed-meshheading:17143520...lld:pubmed
pubmed-article:17143520pubmed:meshHeadingpubmed-meshheading:17143520...lld:pubmed
pubmed-article:17143520pubmed:meshHeadingpubmed-meshheading:17143520...lld:pubmed
pubmed-article:17143520pubmed:meshHeadingpubmed-meshheading:17143520...lld:pubmed
pubmed-article:17143520pubmed:meshHeadingpubmed-meshheading:17143520...lld:pubmed
pubmed-article:17143520pubmed:meshHeadingpubmed-meshheading:17143520...lld:pubmed
pubmed-article:17143520pubmed:meshHeadingpubmed-meshheading:17143520...lld:pubmed
pubmed-article:17143520pubmed:meshHeadingpubmed-meshheading:17143520...lld:pubmed
pubmed-article:17143520pubmed:meshHeadingpubmed-meshheading:17143520...lld:pubmed
pubmed-article:17143520pubmed:meshHeadingpubmed-meshheading:17143520...lld:pubmed
pubmed-article:17143520pubmed:meshHeadingpubmed-meshheading:17143520...lld:pubmed
pubmed-article:17143520pubmed:meshHeadingpubmed-meshheading:17143520...lld:pubmed
pubmed-article:17143520pubmed:meshHeadingpubmed-meshheading:17143520...lld:pubmed
pubmed-article:17143520pubmed:year2007lld:pubmed
pubmed-article:17143520pubmed:articleTitleAutoantibodies to the inhibitor of apoptosis protein survivin in patients with brain tumors.lld:pubmed
pubmed-article:17143520pubmed:affiliationMolecular Neurooncology Laboratory, Department of Neurosurgery, Martin Luther University Halle-Wittenberg, D-06097 Halle, Germany. ariane.soeling@medizin.uni-halle.delld:pubmed
pubmed-article:17143520pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17143520pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:332entrezgene:pubmedpubmed-article:17143520lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:17143520lld:entrezgene
lhgdn:association:35337lhgdn:found_inpubmed-article:17143520lld:lhgdn
lhgdn:association:35361lhgdn:found_inpubmed-article:17143520lld:lhgdn